Oppenheimer raised the firm’s price target on Ensign Group to $135 from $130 and keeps an Outperform rating on the shares. The firm notes Ensign reported solid Q1 results and maintained its strong 2024 outlook. Oppenheimer believes Ensign should benefit from the uncertainty through an improving M&A environment, building on its rapid deal pace.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENSG:
- Ensign Group sees FY24 EPS $5.29-$5.47, consensus $5.39
- Ensign Group reports Q1 adjusted EPS $1.30, consensus $1.28
- The Ensign Group Acquires Long-Term Acute Care Hospital and Skilled Nursing Facility in Utah
- The Ensign Group Acquires Skilled Nursing Facility in Iowa
- The Ensign Group Acquires Healthcare Campus in Arizona